Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
Order Information
Shipping Information
$35 to United States
Products in stock will be shipped in 1-3 business days unless specified.
Key Product Details
Source: | NS0 |
Accession #: | Q9NZQ7 |
Structure / Form: | Disulfide-linked homodimer |
Applications: | Bioactivity |
Complete Your Research
Complete Your Experiment
Citations (15)
Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF include:
-
Species: Human
Sample Types: Whole Cells
Applications: BioassayL Sun et al. (2020), Targeting glycosylated PD-1 induces potent anti-tumor immunity Cancer Res., 0(0):.
PMID: 32156778 -
Species: Human
Sample Types: Recombinant Protein
Applications: BioassayJK Fierle et al. (2019), Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery Sci Rep, 9(1):12815.
PMID: 31492910 -
W Fu et al. (2019), CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity Nat Commun, 10(1):4355.
PMID: 31554797 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayKJ Carpenter et al. (2019), LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer Sci Rep, 9(1):19530.
PMID: 31863071 -
Species: Yeast
Sample Types: Whole Cell
B Cembrola et al. (2019), Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries Biomed Res Int, 2019(0):6051870.
PMID: 31976323 -
Species: Human
Sample Types: Whole Cells
Applications: Flow CytometryA Osa et al. (2018), Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients JCI Insight, 3(19):.
PMID: 30282824 -
Species: N/A
Sample Types: Protein
Applications: BioassayE Burova et al. (2017), Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice Mol. Cancer Ther, 0(0):.
PMID: 28265006 -
Applications: ELISA (Standard)UM Vogl et al. (2017), Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy Anticancer Res., 37(4):1947-1955.
PMID: 28373465 -
Species: Human
Sample Types: Protein
Applications: ELISA (Standard)(2016), B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells Sci Rep, 6(0):36722.
PMID: 27824138 -
Applications: BioassayRobert L Ferris (2016), Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk Oncoimmunology, 5(10):e1200778.
PMID: 27853635 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayLi J et al. (2015), PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res, 75(3):508-18.
PMID: 25480946 -
Species: Human
Sample Types: Serum
Applications: ELISA (Standard)Melendreras S et al. (2014), Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS ONE, 9(12):e113396.
PMID: 25478957 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayChinnadurai R et al. (2014), IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol, 192(4):1491-501.
PMID: 24403533 -
Species: Human
Sample Types: Whole Cells
Applications: BioassaySteidl C et al. (2011), MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 471(7338):377-81.
PMID: 21368758 -
Wan B et al. (2006), Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol., 177(12):8844-50.
PMID: 17142787
There are no citations that match your criteria.
Customer Reviews (21)
Customer Images
-
Application: Binding assay/Protein-protein interactionReason for Rating: Tested binding of PDL1-Fc w/ PD-1 using Octet. KD ~1.5uMVerified Customer | Posted 06/19/2020
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 11/15/2019HEK cells expressing mCherry alone (LEFT) or hPD-1 mCherry (RIGHT) were incubated with 0.25 ug of hPD-L1 hIgG1. Binding was monitored by flow cytometry using an anti-human 488 secondary antibody.
-
Application: Stem/Immune cell maintenance or differentiationVerified Customer | Posted 12/06/2018
-
Application: Cell AdhesionVerified Customer | Posted 10/24/2018
-
Application: Enzymatic activity in vitroVerified Customer | Posted 10/12/2018
-
Application: CellProlifVerified Customer | Posted 09/28/2018
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 08/26/2018
-
Application: SDS-PAGE ControlVerified Customer | Posted 04/12/2018
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 03/30/2018
-
Application: SDS-PAGE ControlVerified Customer | Posted 03/15/2018
-
Application: SDS-PAGE ControlVerified Customer | Posted 03/11/2018
-
Application: Binding assay/Protein-protein interactionReason for Rating: Binding observed.Verified Customer | Posted 02/07/2018
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 12/18/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 12/06/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 12/01/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 11/27/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 11/18/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 07/20/2017
-
Application: Cell AdhesionVerified Customer | Posted 07/20/2017
-
Application: SPR assay for Kinetics between PDL-1 and AntiPDL-1 AntibodyVerified Customer | Posted 07/14/2017SPR experiment
-
Verified Customer | Posted 05/23/2017Using Octet, we tested the ability of B7-H1/PD-L1 to bind recombinant PD-1 (R&D 8986-PD-100) and found them to specifically bind to each other.
There are no reviews that match your criteria.
FAQs
-
The vial is supposed to contain lyophilized protein but it appears to be empty. Is there anything in it?
Pellets can be dislodged during shipping and become disbursed on the vial wall and in the cap. Centrifuge or tap the vial on the benchtop to return this material to the vial bottom. If this does not reveal a pellet, closely inspect the cone of the vial. Some pellets appear as only a tiny amount of material or as a transparent film due to the original buffer formulation. This is a normal appearance for many proteins. For example, if the product is originally lyophilized from a solvent such as acetonitrile or ethanol, and supplied carrier-free, you may not be able to detect the pellet with the naked eye. This does not mean the vial is empty. Reconstitute the vial as directed. After reconstitution, protein concentration can be tested with a spectrophotometer.
-
What is the recommended method for reconstitution of a lyophilized protein or antibody?
Unless more specific directions are on the Certificate of Analysis provided with the product, we suggest the following procedure to ensure optimal recovery: 1. Allow the vial and reconstitution buffer to equilibrate to room temperature. 2. Briefly centrifuge the vial to ensure that all lyophiliate is collected at the bottom of the vial. 3. Add the amount of buffer required to achieve the concentration recommended on the product insert. 4. Allow the vial to reconstitute for 15-30 minutes at room temperature with gentle agitation, like on a rocker platform or rotating by hand. Avoid vigorous shaking that can cause foaming and protein denaturation. 5. Aliquot into volumes greater than 20 μL and store as indicated on the product insert. If the vial exhibits flakes or particulates, mix the product for a couple of hours at room temperature and then at 4oC overnight. Contact Technical Service if product does not go into solution.
-
Are R&D Systems recombinant proteins and antibodies sterile?
Although the vials are bottled using aseptic techniques, heat-treated vials, and sterile stock solutions, they are not considered or guaranteed to be sterile. If sterile material is needed for an experiment, the material can be filtered through a 0.2 micron filter designed for use with biological fluids.
-
What is the pI (Isoelectric Point) of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7)?
The calculated pI for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7) is 7.1.
-
Do you have a human IgG1 Fc region that would be a suitable negative control for the linker sequence and Fc region in Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?
Yes, we offer Recombinant Human IgG1 Fc Protein, CF (Catalog # 110-HG), which contains the human IgG Fc region and linker sequence.
-
Has Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7), been evaluated on primary cells?
Bioactivity of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7) is evaluated by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocyte primary cells. The ED50 for this effect is 0.075-0.75 μg/mL. We recommend reviewing our list of publications under the Citations tab on the product-specific web page to find reported use of our products in similar experimental layouts.